ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026

Reuters03-27

ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026

ADMA issued a statement disputing allegations in a Culper Research report and said it reviewed the claims and found them misleading and inaccurate.
Data cited by the company from distributors and direct customers showed ASCENIV end-user demand has increased over the past two-plus years.
Distributor inventory data cited by ADMA showed ASCENIV averaged 128 days of inventory on hand as of January 5, 2026 and 90 days as of March 22, 2026.
ADMA said ASCENIV is used as a late-line therapy for immune-compromised patients and is positioned differently from standard immune globulin products.
The company said its audits for 2024 and 2025 received unqualified opinions and it has not had undisclosed related-party transactions involving the Grossman family.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679602) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622823346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622823346","market":"us","top_or_hot":-1,"title":"ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          ADMA issued a statement disputing allegations in a Culper Research report and said it reviewed the claims and found them misleading and inaccurate.\n        </li>\n<li>\n          Data cited by the company from distributors and direct customers showed ASCENIV end-user demand has increased over the past two-plus years.\n        </li>\n<li>\n          Distributor inventory data cited by ADMA showed ASCENIV averaged 128 days of inventory on hand as of January 5, 2026 and 90 days as of March 22, 2026.\n        </li>\n<li>\n          ADMA said ASCENIV is used as a late-line therapy for immune-compromised patients and is positioned differently from standard immune globulin products.\n        </li>\n<li>\n          The company said its audits for 2024 and 2025 received unqualified opinions and it has not had undisclosed related-party transactions involving the Grossman family.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679602) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          ADMA issued a statement disputing allegations in a Culper Research report and said it reviewed the claims and found them misleading and inaccurate.\n        </li>\n<li>\n          Data cited by the company from distributors and direct customers showed ASCENIV end-user demand has increased over the past two-plus years.\n        </li>\n<li>\n          Distributor inventory data cited by ADMA showed ASCENIV averaged 128 days of inventory on hand as of January 5, 2026 and 90 days as of March 22, 2026.\n        </li>\n<li>\n          ADMA said ASCENIV is used as a late-line therapy for immune-compromised patients and is positioned differently from standard immune globulin products.\n        </li>\n<li>\n          The company said its audits for 2024 and 2025 received unqualified opinions and it has not had undisclosed related-party transactions involving the Grossman family.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679602) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL244Jk1:1","article_id":"2622823346","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622823346","pubTimestamp":1774609331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026. ADMA issued a statement disputing allegations in a Culper Research report and said it reviewed the claims and found them misleading and inaccurate.Data cited by the company from distributors and direct customers showed ASCENIV end-user demand has increased over the past two-plus years.Distributor inventory data cited by ADMA showed ASCENIV averaged 128 days of inventory on hand as of January 5, 2026 and 90 days as of March 22, 2026.ADMA said ASCENIV is used as a late-line therapy for immune-compromised patients and is positioned differently from standard immune globulin products.The company said its audits for 2024 and 2025 received unqualified opinions and it has not had undisclosed related-party transactions involving the Grossman family.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4112":"金融交易所和数据","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ADMA":"ADMA Biologics Inc","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"ADMA Biologics驳斥Culper研究指控；截至2026年1月5日和2026年3月22日，ASCENIV经销商库存平均为128天和90天","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":0.9,"NDAQ":0.9},"content_text":"ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026\n    \n\n\n          ADMA issued a statement disputing allegations in a Culper Research report and said it reviewed the claims and found them misleading and inaccurate.\n        \n\n          Data cited by the company from distributors and direct customers showed ASCENIV end-user demand has increased over the past two-plus years.\n        \n\n          Distributor inventory data cited by ADMA showed ASCENIV averaged 128 days of inventory on hand as of January 5, 2026 and 90 days as of March 22, 2026.\n        \n\n          ADMA said ASCENIV is used as a late-line therapy for immune-compromised patients and is positioned differently from standard immune globulin products.\n        \n\n          The company said its audits for 2024 and 2025 received unqualified opinions and it has not had undisclosed related-party transactions involving the Grossman family.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679602) on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622823346","isCrawlerRequest":true}